Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI) Cilastatin is parti...
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and O...
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation No...